Experimental cell therapy targets Hard-to-Treat sarcoma

NCT ID NCT05549921

Terminated Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested a new cell therapy called TAEST16001 in 8 adults with advanced soft tissue sarcoma that had stopped responding to standard treatments. The therapy uses specially engineered immune cells to attack cancer cells that carry a specific marker (NY-ESO-1) in patients with a particular genetic type (HLA-A*02:01). The study aimed to see if the treatment could shrink tumors, but it was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TAEST16001 cells (a type of immune cell therapy)
What this could lead to: If successful, this could point toward a new treatment option for advanced soft tissue sarcoma in patients with specific genetic markers.
What could go wrong: This is a very early, small study (only 8 participants) that was terminated, so results are limited. The therapy may not work or could have serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOFT TISSUE SARCOMA

Contacts and locations

Locations

Peking University Cancer Hospital & Institute

Beijing, 100142, China
Sun Yat-Sen Univerisity Cancer Center

Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.